Wide Ranks

ADXN

Addex Therapeutics Ltd

8.62

Top Statistics
Market Cap 9 M Forward PE -172.48 Revenue Growth -81.80 %
Current Ratio 4.97 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 500.16 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -71.67 Enterprise / Revenue 919.15 Price To Sales Trailing12 Months 10.68
Profitability
Profit Margins 500.16 % Operating Margins -780.13 %
Balance Sheet
Total Cash 3 M Total Cash Per Share 0.0390 Total Debt 32182
Total Debt To Equity 0.2540 Current Ratio 4.97 Book Value Per Share 0.0090
All Measures
Short Ratio 14.00 % Message Board Id finmb_2573627 Fax 41 22 884 1556
Shares Short Prior Month 9605 Return On Equity -1.26 City Geneva
Uuid 38807d1a-b771-3feb-99eb-88558227ef73 Previous Close 8.58 First Trade Date Epoch Utc 1 B
Book Value 0.0090 Beta 1.87 Total Debt 32182
Volume 24691 Price To Book 958.23 Last Split Date 1 B
Fifty Two Week Low 5.00 Total Cash Per Share 0.0390 Total Revenue 863232
Shares Short Previous Month Date 1 B Target Median Price 30.00 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -780.13 % Target Mean Price 30.00
Net Income To Common -11856761 Short Percent Of Float 0.0041 Implied Shares Outstanding 1 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 60650
Average Volume10days 60650 Total Cash 3 M Next Fiscal Year End 1 B
Revenue Per Share 1.20 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 8.58 Target Low Price 30.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.78 Open 8.83
Free Cashflow -5807696 Dividend Yield 0.00 % Return On Assets -0.6171
Time Zone Short Name EST Trailing Eps -21.66 Day Low 8.38
Address1 Chemin des Mines, 9 Shares Outstanding 1 M Price Hint 2
Target High Price 30.00 Website https://www.addextherapeutics.com 52 Week Change 0.5539
Average Volume 43820 Forward Eps -0.0500 Recommendation Key none
Quick Ratio 467.00 % Last Split Factor 1:20 Regular Market Day High 8.94
Is_sp_500 False Profit Margins 500.16 % Debt To Equity 0.2540
Fifty Two Week High 27.90 Day High 8.94 Shares Short 3461
Regular Market Open 8.83 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 919.15 Revenue Growth -81.80 % Shares Percent Shares Out 0.0032
Operating Cashflow -7826565 Currency USD Time Zone Full Name America/New_York
Market Cap 9 M Is_nasdaq_100 False Zip 1202
Quote Type EQUITY Industry Biotechnology Long Name Addex Therapeutics Ltd
Regular Market Day Low 8.38 Held Percent Institutions 0.0017 Current Price 8.62
Enterprise To Ebitda -71.67 Financial Currency CHF Current Ratio 4.97
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country Switzerland
Float Shares 34 M Two Hundred Day Average 10.42 Enterprise Value 793 M
Price To Sales Trailing12 Months 10.68 Forward PE -172.48 Regular Market Volume 24691
Ebitda -11070066 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

The company focuses on the discovery of G-protein coupled receptors and enzymes.

Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.

Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.

The company was formerly known as Addex Pharmaceuticals Ltd.

Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.